Agrawal Sachin, Brown Christian T, Bellamy Elizabeth A, Kulkarni Ravi
Department of Urology, St Peter's Hospital, Chertsey, UK.
BJU Int. 2009 Feb;103(3):372-6. doi: 10.1111/j.1464-410X.2008.08018.x. Epub 2008 Sep 3.
To review our long-term use of the thermo-expandable metallic ureteric stent, (model 051, PNN Medical, Denmark) for ureteric obstruction, and review current reports on its use.
Data were collected prospectively on all patients who had a Memokath 051 ureteric stent inserted between November 1996 and November 2007. The standard stent, and wide and dual expansion versions were used. The stricture characteristics were recorded in a standard way. All stents were inserted by one surgeon in the UK and internationally, following a standard protocol.
In all, 74 stents were inserted into 55 patients in the study period (mean age 60 years, range 11-90). The indications for metallic stenting included primary stenting for malignancy, failed conventional open and endoscopic techniques, palliation, and where significant comorbidity limited repetitive stent changes. In 28 patients the obstruction was caused by malignancy, whereas in 27 it was caused by recurrent benign disease. The mean (range) hospital stay was 1.43 (0-7) days. Imaging after insertion showed normal or improved functional drainage in all but three patients, with immediate complications including urinary extravasation (one), poor thermo-expansion (one) and equipment failure (locking assembly) (one). Late complications included migration (13), encrustation (two) and fungal infections (three). In all, 14 patients needed reinsertion (mean of 7.1 months, range 1-14) after insertion for migration (eight), encrustation (two), stricture progression (three) and incorrect stent length (one). Overall, 29 patients have died with the stents in-situ. The mean (range) follow-up was 16 (4-98) months.
The thermo-expandable metallic Memokath 051 ureteric stent offers effective and durable long-term relief from ureteric obstruction, and is a safe alternative to conventional JJ stenting. In addition there is an emerging role in palliation and the primary management of ureteric strictures.
回顾我们长期使用热膨胀性金属输尿管支架(051型,PNN Medical,丹麦)治疗输尿管梗阻的情况,并综述当前关于其使用的报告。
前瞻性收集1996年11月至2007年11月期间所有植入Memokath 051输尿管支架的患者的数据。使用了标准支架、宽扩张型和双扩张型支架。以标准方式记录狭窄特征。所有支架均由英国及国际上的一名外科医生按照标准方案植入。
在研究期间,共对55例患者植入了74枚支架(平均年龄60岁,范围11 - 90岁)。金属支架置入的适应证包括恶性肿瘤的初次支架置入、传统开放和内镜技术失败、姑息治疗以及严重合并症限制重复更换支架的情况。28例患者的梗阻由恶性肿瘤引起,27例由复发性良性疾病引起。平均(范围)住院时间为1.43(0 - 7)天。植入后影像学检查显示,除3例患者外,其余患者的功能引流均正常或改善,即刻并发症包括尿外渗(1例)、热膨胀不良(1例)和设备故障(锁定组件)(1例)。晚期并发症包括移位(13例)、结壳(2例)和真菌感染(3例)。共有14例患者在植入后因移位(8例)、结壳(2例)、狭窄进展(3例)和支架长度错误(1例)需要再次植入(平均7.1个月,范围1 - 14个月)。总体而言,29例患者在支架在位时死亡。平均(范围)随访时间为16(4 - 98)个月。
热膨胀性金属Memokath 051输尿管支架能有效、持久地缓解输尿管梗阻,是传统双J支架的安全替代方案。此外,在姑息治疗和输尿管狭窄的初次治疗中也发挥着越来越重要的作用。